Overview

Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer

Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
Randomized,non-blinded,multi-center study in patients with metastatic breast cancer.Patients will be treated with docetaxel or docetaxel-gemcitabine. Aim of the study is to assess the optimal dosage and safety in this setting.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Docetaxel
Gemcitabine